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Background: Idiopathic infantile arterial calcification (IIAC) is a rare autosomal recessive disorder, characterized by
wide spread calcifications in arterial walls, leading to vaso-occlusive ischaemia of multiple organs. Mortality is high,
and there is no definitive treatment.
Case presentation: A male neonate, 36+5 weeks gestation, 2.81 kg, was admitted to NICU for respiratory distress.
At one hour of age, he was noted to be pale, hypoperfused, with weak pulses, a hyperdynamic precordium and a
grade IV/VI pansystolic murmur. The rest of his examination was normal. A chest X-ray showed massive
cardiomegaly and pulmonary oedema. An echocardiogram (ECHO) indicated moderate persistent pulmonary
hypertension (PPHN) of unclear etiology. A diagnosis of Idiopathic infantile arterial calcification was made and a trial
of Editronate therapy was given without success.
Conclusion: IIAC is a rare disorder, it should be considered whenever a neonate presents with unexplainable
cardiac failure, PPHN, echogenic vessels on X-ray/ultrasound and, or concentric hypertrophic ventricles on ECHO.
Serial antenatal ultrasound findings of echogenic cardiac foci should raise the suspicion of IIAC. Further studies to
determine the long term effects of Editronate on vascular calcifications, disease outcome, and other treatment
options are needed.
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Idiopathic infantile arterial calcification (IIAC) is a rare
autosomal recessive disorder associated with widespread
calcification and degeneration of the elastic lamina of ar-
teries [1]. Clinical manifestations are related to vaso-
occlusive disease of multiple organs [2].The association
of IIAC with persistent pulmonary hypertension (PPHN)
is rare [3,4]. We describe a newborn with IIAC who
presented with PPHN and cardiac failure.
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reproduction in any medium, provided the orfor respiratory distress. The family history was notable
for parental consanguinity. He was delivered to a G2 P1
mother after an uncomplicated pregnancy by emergency
caesarean section for fetal heart rate abnormalities.
Apgar scores were 91 and 95, with no resuscitation required.
At one hour of age, he was noted to be pale, hypoperfused,
with weak pulses, a hyperdynamic precordium and a grade
IV/VI pansystolic murmur. The rest of his examination was
normal. A chest x-ray showed massive cardiomegaly and
pulmonary oedema. An echocardiogram (ECHO) indicated
moderate PPHN. He required intubation, and treatment
with inhaled nitric oxide (iNO), sildenafil, furosemide and
milrinone.
Complete blood counts, electrolytes, blood cultures,
enterovirus panel, metabolic investigations and cardiac
enzymes were normal. Molecular genetic testing for
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Figure 2 Ultrasound of abdomen showing calcified aorta.
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stroke-like episodes (MELAS) and Neuropathy, Ataxia,
and Retinitis Pigmentosa (NARP) syndrome was negative.
Repeated ECHO examinations showed normal systemic
and pulmonary venous drainage, thickened semilunar and
tricuspid valve leaflets, and concentric left ventricular
hypertrophy. An ECG was negative for ischaemic changes.
Computed chest angiography showed incidental mild
narrowing of the left pulmonary vein, which was not no-
ticed in any of the ECHO examinations.
A detailed review of an abdominal X-ray (Figure 1),
and computed tomography (CT) scan found calcified
vessels, suggested the clinical diagnosis of IIAC on day
20 of life. An ECHO on day 20 of life also identified an
echogenic aorta, echogenic coronary arteries with nor-
mal pulmonary veins. Echodensities were also noticed
in the main and branch pulmonary arteries. Calcifica-
tions of the abdominal aorta (Figure 2), renal artery and
intracranial thalamic vessels were also evident on ultra-
sound. No mutation of ectonucleotide pyrophosphatase/
phosphodiesterase 1 (ENPP1) gene was identified. Blood
was stored for DNA banking to identify mutations in
other genetic sequences.
The baby was extubated on day 20, iNO and milirinone
were discontinued gradually. The Sildenafil was tapered to
1 mg/kg/day. The infant’s subsequent course in NICU was
complicated by recurrent abdominal distension, feeding
intolerance, irritability, pyrexia and systemic hypertension.Figure 1 Abdominal X-ray showing calcified descending aorta.Oral Editronate Sodium (10 mg/kg/day, twice a day)
was started on day 40. He was discharged home at 75 days
of age on Editronate 20 mg/kg/day; Sildenafil 1.5 mg/kg/
day; and Captopril 1.2 mg/kg/day. He developed fever and
respiratory distress one day after discharge, requiring re-
admission. The respiratory viral panel, and sepsis work up
were normal but troponin was elevated (0.53 ug/L, normal
value 0.0-0.1 ug/L). Twelve leads ECG was not available
but a tracing showed S-T segment elevation in lead II. Re-
suscitation code was revised. Palliative care was initiated
with parental consent, and no escalation of pulmonary
hypertension therapy was advised. Despite ventilatory and
inotropic support for hypotension, he died at three months
of age. The parents declined consent for autopsy, skin/
arterial biopsy and sibling genetic screening.
Discussion
IIAC was first described in 1901 [1]. It is clinically and gen-
etically a heterogeneous disease [2,5,6]. The most described
pathogenesis in 80% of cases is a mutation and inactivation
of ectonucleotide pyrophosphatase/phosphodiesterase 1
(ENPP1) gene [7-11]. ENPP1 is expressed on fibroblasts,
osteoblasts and hepatocytes [7]. ENPP1 gene has nucleo-
tide pyrophosphohydrolase activity and produces inorganic
pyrophosphate (PPi) [11]. PPi prevents deposition of cal-
cium hydroxyapatite crystal in the arteries. The mutation
of ENPP1 gene results in variable degrees of calcification
and intimal fibrosis of medium and large arteries of cardiac
and renal vascular system [9]. There are other known
(ABCC6, NT5E and SLC 20A2) and unknown gene muta-
tions, associated with arterial calcification [5,12,13].
A literature review stated that almost 48% of patients
presented at birth or in-utero, while 52% cases were
identified during infancy [1]. Fetal complications include:
cardiac arrhythmias, heart failure, hydrops fetalis and
fetal demise, often early in pregnancy [2,14,15]. During
the neonatal period, 30-40% of infants presented with re-
spiratory or cardiac failure [1]. Seizures, renal failure,
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were seen in 1% to 8% of neonates [1]. In infants, com-
mon manifestations include: irritability, feeding difficul-
ties and poor growth [1]. Coronary artery calcification
was the worst prognostic indicator and majority of in-
fants expired due to myocardial infarction [1,16].
IIAC is a diagnosis of exclusion [2]. Absence of other
infantile arterial calcification disorders, normal serum
calcium/phosphrous panel and a positive family history
suggest IIAC [1]. The gold standard for diagnosis is ar-
terial biopsy [1,8,10,17]. Evidence of calcified arterial
walls on X-rays of the chest/abdomen and long bones,
CT of chest, ECHO, cranial and abdominal ultrasound
are other helpful diagnostic findings [2,8].
Antenatal screening can be done by DNA analysis for
ENPP1 mutation and by serial ultrasounds [15]. Detection
of echogenic intracardiac foci, arterial calcification, dilated
or hypertrophied cardiac chambers, hydrops fetalis are
strong indicators of IIAC [14]. Families can be screened
for calcified arteries by performing ultrasounds, X-rays
and echocardiography [15].
In the literature only few cases of IIAC with PPHN
have been reported [4,10]. One patient received Editronate
15 mg/kg/day, but had remained hypertensive, ventilator
dependant and died at 35 days of life [10]. Extensive calci-
fication of major vessels was confirmed on autopsy. Our
patient also had PPHN with other systemic signs attribut-
able to IIAC.
Reports in the literature suggest resolution of arterial
calcification with Editronate (Biphosphonate sodium)
treatment [8,18]. The longest survival has been reported
in a 25-year-old man who was treated with Editronate
(Biphosphonate sodium) [1]. However, all patients who
received Editronate had mild or no evidence of coronary
involvement. Editronate is an analogue of PPi [8]. It al-
ters the calcium balance by interfering with hydroxyapa-
tite crystal formation and inhibits the calcium deposition
in the existing calcified lesions. The recommended dose
and duration of this treatment varies in the literature [8,18].
Our patient was maximized to 20 mg/kg/day, twice a day.
Serial calcium, phosphate, alkaline phosphatase and wrist
X-rays were done to monitor the side effects of the drug
[18,19]. Vitamin D was also given to prevent Editronate in-
duced vitamin D deficiency. No resolution of calcification
was seen in the serial radio-imaging studies.
Our patient also had coronary artery calcification, a
common cause of sudden ischemic heart failure [1]. We
assumed that myocardial ischemia was the probable cause
of death because of high troponin levels. Arterial biopsy
and autopsy were not performed as per parent’s wishes.
Conclusions
Though IIAC is a rare disorder, it should be considered
whenever a neonate presents with unexplainable cardiacfailure, PPHN, echogenic vessels on X-ray/ ultrasound and,
or concentric hypertrophic ventricles on ECHO. Serial
antenatal ultrasound findings of echogenic cardiac foci
should raise the suspicion of IIAC. Every effort should be
made to establish the diagnosis by arterial and skin fibro-
blast biopsy. Further studies to determine the long term
effects of Editronate on vascular calcifications, disease out-
come, and other treatment options are needed.
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